ArticleJACC. Asia2026
Medication Adherence and Antithrombotic Therapy Outcomes: Insights From a Post Hoc Analysis of the AFIRE Trial.
Article in JACC. Asia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02642419 (Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study (AFIRE Study)
Who cites it
1 citing paper in PubMed.
- Drugs Don't Work in Patients Who Don't Take Them.JACC. Asia · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe AFIRE (Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease) trial demonstrated that rivaroxaban monotherapy has noninferior efficacy and superior safety compared with combination therapy (rivaroxaban plus a single antiplatelet) in patients with atrial fibrillation and stable coronary artery disease.
objectivesThis post hoc analysis aimed to explore the impact of medication adherence on the AFIRE trial results.
methodsA total of 2,120 patients were categorized into adherent and nonadherent groups based on self-reported assessments, which were further validated through on-site visits to the facilities. Adherence was defined as continuous medication use as prescribed. The primary efficacy endpoint was a composite of stroke, systemic embolism, myocardial infarction, revascularization requiring unstable angina, or all-cause death. The primary safety endpoint was major bleeding events.
resultsAmong the 2,012 (94.9%) adherent patients, rivaroxaban monotherapy showed significantly better outcomes compared with combination therapy regarding both efficacy (HR: 0.72; 95% CI: 0.53-0.96; P = 0.028) and safety (HR: 0.63; 95% CI: 0.41-0.97; P = 0.034). However, no significant differences in outcomes were shown in nonadherent patients (n = 108). There was no interaction between medication adherence and the randomized treatment group. In clinically high-risk patients with a history of angina pectoris, compared with nonadherent patients (n = 68), those who demonstrated medication adherence (n = 1,281) exhibited significantly better efficacy outcomes (HR: 0.52; 95% CI: 0.30-0.97; P = 0.041).
conclusionsHigh adherence to rivaroxaban monotherapy was associated with improved outcomes, underscoring the importance of adherence in achieving optimal therapeutic effects (Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease [AFIRE], NCT02642419; AFIRE Study: Atrial Fibrillation and Ischemic events with Rivaroxaban in patiEnts with stable coronary artery disease Study, UMIN000016612).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.